Drug Overview

Ruxotemitide (widely known in medical research as NBTXR3) is an incredibly innovative “Smart Drug” designed to change the way we treat cancer. It belongs to a cutting-edge class of treatments called Targeted Therapy and “radioenhancers.” Unlike traditional chemical medicines that travel through your entire body, ruxotemitide is a liquid made of billions of microscopic particles (nanoparticles) that is injected directly into a tumor.

In the international medical community, ruxotemitide is a breakthrough. It is designed to act as a multiplier for radiation therapy. When a patient receives standard radiation, these injected nanoparticles absorb the X-rays and release a massive burst of energy inside the cancer cell, destroying the tumor from the inside out while protecting the healthy tissues around it.

Generic Name: Ruxotemitide (Investigational code: NBTXR3)
US Brand Names: None (Currently an investigational drug in the US; marketed as Hensify in Europe)
Drug Class: Hafnium Oxide Nanoparticle; Radioenhancer
Route of Administration: Intratumoral Injection (Injected directly into the cancer)
FDA Approval Status: Investigational (Granted “Fast Track” designation by the FDA for certain cancers; CE-marked for use in Europe for soft tissue sarcoma)

What Is It and How Does It Work? (Mechanism of Action)

To understand how ruxotemitide works, you have to look at the physics of radiation therapy. Normally, radiation beams pass through the body and hit cancer cells, causing enough damage to kill them. However, doctors are limited in how much radiation they can use because it also damages healthy cells.

Ruxotemitide is made of hafnium oxide, a very dense metal that acts like a sponge for radiation.

At the molecular level, this “Smart Drug” works through a fascinating process:

Direct Delivery: The nanoparticles are injected right into the tumor. Because they are so tiny, they easily slip inside the cancer cells and stay there. They do not leak out into the rest of the body.
Energy Absorption: When the patient receives their standard radiation treatment, the X-rays hit the hafnium oxide nanoparticles. Because hafnium is so dense, it absorbs the X-ray energy much faster than the surrounding human tissue.
The Electron Burst (Auger Effect): Once the nanoparticle absorbs the X-ray, it releases a massive, localized burst of secondary electrons (called Auger electrons).
Shattering the DNA: These electrons act like a microscopic bomb going off inside the cancer cell. They smash into the cancer cell’s DNA (its instruction manual) and completely shatter it.
Cell Death: Because the DNA is broken beyond repair, the cancer cell dies. The healthy cells nearby survive because the intense electron burst only travels a microscopic distance from the nanoparticle.

FDA-Approved Clinical Indications

Because ruxotemitide is still an investigational drug in the United States, it is not yet fully approved by the FDA for general hospital use. It is available to patients participating in strictly monitored clinical trials. (Note: It is approved in Europe under the brand name Hensify for specific soft tissue cancers).

Oncological Uses (Investigational):
- Head and Neck Squamous Cell Carcinoma: Investigated heavily for older adults who cannot safely handle harsh chemotherapy.
- Soft Tissue Sarcoma: Used to shrink tumors in the muscles or fat before surgery.
- Pancreatic Cancer: Investigated as a way to make radiation more effective on hard-to-reach tumors.
- Liver and Prostate Cancers: Currently in early research phases.
Non-oncological Uses:
- There are no non-oncological uses for this medication.

Dosage and Administration Protocols

Ruxotemitide is not a pill or an IV drip. It is a one-time injection given by a specialized doctor (like an interventional radiologist or surgeon) while you are in the hospital or clinic.

Parameter	Standard Investigational Protocol
Typical Dose	Based on the size of the tumor, not your body weight.
Calculated Volume	Usually a liquid volume equal to 22% of the tumor’s total size.
Frequency	A single, one-time injection.
Timing	Given 1 to 2 days before your first radiation therapy session begins.
Route	Intratumoral injection (using imaging like an ultrasound or CT scan to guide the needle exactly into the tumor).

Dose Adjustments:

Renal (Kidney) and Hepatic (Liver) Insufficiency: Because ruxotemitide is injected directly into the tumor and is physically inert (it does not break down or circulate through the blood to be processed by your organs), standard dose reductions for liver or kidney problems are generally not required.

Clinical Efficacy and Research Results

Recent clinical studies from 2020 through 2025 show that ruxotemitide is a highly promising tool for shrinking tumors that are difficult to treat with radiation alone.

Soft Tissue Sarcoma Success: In major European trials, patients who received the nanoparticle injection before radiation had a much higher “pathological complete response” rate than those who only had radiation. This means that when surgeons went to remove the tumor later, they found significantly more dead cancer tissue, making the surgery easier and more successful.
Head and Neck Cancer: In ongoing US and international trials for head and neck cancers, general numerical data indicates that using ruxotemitide helps control the tumor locally (keeping it from growing or spreading in the neck) much better than radiation alone, which is vital for patients who cannot survive traditional chemotherapy.
Disease Progression: Overall, by maximizing the power of radiation, research shows this drug helps halt the progression of the localized disease, giving patients a better chance at long-term tumor control.

Safety Profile and Side Effects

Black Box Warning:

None. (Because it is an investigational drug in the US, it does not carry a formal FDA Black Box Warning. It is generally considered very safe because the drug stays inside the tumor).

Common Side Effects (>10%)

Injection Site Pain: Mild to moderate soreness or swelling where the needle went into the skin and tumor.
Radiation Dermatitis: Redness, peeling, or a sunburn-like rash on the skin over the tumor (this is caused by the radiation therapy, not the drug itself).
Fatigue: Feeling unusually tired during your weeks of radiation.

Serious Adverse Events

Tumor Pain: As the tumor rapidly dies from the inside, it can sometimes cause deep swelling and pain.
Infection: Any time a needle enters the body, there is a small risk of bacterial infection at the injection site.
Bleeding: A risk of bleeding inside the tumor from the injection needle, especially in highly vascular tumors.

Management Strategies

Pain Control: Doctors will give you a local numbing shot before the procedure and can prescribe standard pain relievers for the days following the injection.
Wound Care: Keep the injection site clean and dry. Your care team will provide special creams to soothe any radiation sunburns.

Connection to Immunotherapy and Regenerative Medicine

One of the most exciting research areas for ruxotemitide is its role in Immunotherapy. Cancer cells often hide from the body’s immune system (known as “cold” tumors). When ruxotemitide shatters the cancer cells with radiation, the cells burst and spill all of their hidden proteins into the body. This process is called “immunogenic cell death.”

Current clinical trials are testing what happens when you combine ruxotemitide with modern immune-boosting drugs (like PD-1 checkpoint inhibitors). The shattered tumor acts like a natural vaccine, waking up the patient’s immune system. The immune cells then learn what the cancer looks like, regenerate their forces, and travel through the body to hunt down and destroy any other cancer cells that may have spread to different organs.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

High-Resolution Imaging: An MRI or CT scan is absolutely required so the doctor can precisely measure the exact 3D volume of your tumor to calculate the correct dose of nanoparticles.
Blood Tests: Standard blood tests to ensure your blood clots normally before receiving a deep needle injection.

Precautions During Treatment

Scheduling is Critical: You must coordinate perfectly between the doctor giving the injection and the doctor giving the radiation. The radiation must usually start within a day or two of the injection for the best results.
Movement: Depending on where the tumor is, you may need to rest for a few hours after the injection to ensure the liquid stays perfectly in place.

“Do’s and Don’ts” List

Do ask your doctor exactly what to expect during the injection procedure (e.g., if you will be awake or lightly sedated).
Do attend every single scheduled radiation appointment. The “Smart Drug” will not work unless the radiation X-rays are there to activate it.
Do tell your care team right away if the injection area becomes hot, extremely red, or starts leaking fluid, as this could be an infection.
Don’t rub, massage, or apply deep pressure to the tumor area after the injection.
Don’t apply heating pads or ice packs to the treated area unless your radiation oncologist specifically tells you it is safe.

Legal Disclaimer

Standard medical information disclaimer: This guide is intended for educational and informational purposes only and does not constitute medical advice. Ruxotemitide (NBTXR3) is an investigational medication in the United States and is only available to patients participating in approved clinical research trials. Always consult with a licensed oncologist, radiation oncologist, or healthcare professional to discuss your specific diagnosis, available treatment options, and potential risks. This content reflects clinical and research data available as of early 2026.